Novartis has halted eight trials of its cellular therapy rapcabtagene autoleucel in patients with rheumatic and neurological ...

Novartis, BMS reportedly halt trials; first serious blow to burgeoning field ...

Novartis halted eight clinical trials of an experimental therapy targeting autoimmune and neurological disorders in late ...

Novartis paused 8 trials of its rap-cel therapy after patients died from a severe immune reaction; Bristol Myers followed as a precaution ...

Novartis suspended multiple studies of a CAR T candidate after three patients who received the therapy suffered fatal cases ...

Novartis has halted eight rap-cell clinical trials after three patients died following severe immune reactions linked to the CAR-T therapy.

Novartis and Bristol Myers Squibb have halted several CAR-T trials in autoimmune diseases due to immune-related adverse events, Fierce has learned. | Novartis and Bristol Myers Squibb have halted ...

Large pharmaceutical firm Novartis confirmed that it is halting and investigating several clinical trial programs involving ...

Extending CAR T beyond cancer alters risk–benefit calculus, because chronic autoimmune populations have alternative therapies ...

Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is a standard treatment for relapsed or refractory B-cell non-Hodgkin lymphomas. Long-term results and curative potential remain uncertain. We ...

Immunotherapies strengthen the body's own anticancer defenses in a highly targeted manner. In therapies using so-called CAR T ...